DxNA
Saint George, Utah, United States
About DxNA
DxNA LLC develops and manufactures high value molecular diagnostic instruments/platforms and tests with an emphasis in the area of infectious diseases. The company’s primary focus is on bringing the benefits of molecular testing to underserved community hospitals and clinics so that diagnostic information is more readily and quickly available. Using this information in a timelier manner has been shown to impact clinical decision making, improve patient outcomes and lower treatment costs. To make molecular testing available to more patients, the company has developed the GeneSTAT® System™ as its first instrument system. This novel, patented and highly portable instrument is combined with a proprietary test cartridge to provide easy to use, rapid and affordable Real-Time PCR molecular testing capabilities that are ideal for low to moderate throughput locations. Examples of target markets for the GeneSTAT System include small to mid-sized community hospitals, clinics, and rural healthcare facilities where high cost & high volume instruments requiring specially trained laboratory technicians are not viable.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $6.6M
- Last round: Series Unknown (Dec 2015)
- Website: dxna.com
- Phone: (435)628-0324
Industries & Categories
Biotechnology, Clinical Trials, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/dxna-2488626 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.